The Hainan Boao Lecheng Pilot Zone Management Bureau announced the implementation of Baclofen Intrathecal Sintetica, a special treatment for severe spasms, at the Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine and Hainan Boao Research Hospital. This therapy is suitable for patients with severe spinal cord-derived chronic spasticity (related to injury, multiple sclerosis, or other spinal cord diseases) or brain-derived spasticity who have not responded to oral anticonvulsants (including oral diclofenac) and/or have experienced unacceptable side effects within effective oral doses.
Baclofen Therapy Background
Baclofen, a muscle relaxant used for treating abnormal or disabling spastic tension, has been approved in the US for the treatment of spinal cord spasticity and subsequently for brain-derived spasms. Oral baclofen, whose efficacy is limited by the blood-brain barrier, is prone to systemic side effects such as drowsiness and mental confusion. In contrast, Baclofen intrathecal injection therapy improves the administration route by directly infusing the drug into the subarachnoid space, bypassing the blood-brain barrier, and significantly relieving spasms with minimal dosage. This not only greatly enhances the therapeutic effect but also reduces side effects such as sedation, significantly improving the quality of life of patients.-Fineline Info & Tech
